Research Topics
| Weibo CaiSummaryAffiliation: University of Wisconsin Country: USA Publications
| Collaborators
|
Detail Information
Publications
Multimodality molecular imaging of tumor angiogenesisWeibo Cai
Department of Radiology and Medical Physics, School of Medicine and Public Health, University of Wisconsin Madison, Madison, Wisconsin 53792 3252, USA
J Nucl Med 49:113S-28S. 2008..Not limited to cancer, these novel agents can also have broad applications for many other angiogenesis-related diseases...
Imaging of integrins as biomarkers for tumor angiogenesisWeibo Cai
The Molecular Imaging Program at Stanford, Department of Radiology and Bio X Program, Stanford University School of Medicine, California, USA
Curr Pharm Des 14:2943-73. 2008..In the new era of personalized medicine, fast clinical translation and incorporation of integrin imaging into anti-cancer clinical trials will be critical for the maximum benefit of cancer patients...- Editorial: PET tracers based on nonstandard radionuclidesWeibo Cai
Curr Radiopharm 4:75. 2011 
Tumor-targeted drug delivery with aptamersY Zhang
Department of Medical Physics, School of Medicine and Public Health, University of Wisconsin Madison, Madison, Wisconsin 53705 2275, USA
Curr Med Chem 18:4185-94. 2011..Therefore, future directions and challenges in aptamer-based drug delivery are also discussed...- Molecular imaging with nucleic acid aptamersH Hong
Department of Radiology, University of Wisconsin Madison, 1111 Highland Ave, Madison, WI 53705 2275, USA
Curr Med Chem 18:4195-205. 2011.... - Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculatureWeibo Cai
Molecular Imaging Program at Stanford MIPS, Department of Radiology, and Bio X Program, Stanford University School of Medicine, Stanford, CA 94305 5484, USA
J Nucl Med 48:1862-70. 2007..The development of a dual-function PET/near-infrared fluorescence (NIRF) probe can allow for accurate assessment of the pharmacokinetics and tumor-targeting efficacy of QDs... - (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expressionZi Bo Li
Molecular Imaging Program at Stanford, Department of Radiology and Bio X Program, Stanford University School of Medicine, Stanford, California 94305, USA
J Nucl Med 48:1162-71. 2007..In this study, we developed (64)Cu-labeled multimeric RGD peptides, E{E[c(RGDyK)](2)}(2) (RGD tetramer) and E(E{E[c(RGDyK)](2)}(2))(2) (RGD octamer), for PET imaging of tumor integrin alpha(v)beta(3) expression... - The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma modelAnand Veeravagu
Department of Neurosurgery, Stanford University School of Medicine, 1201 Welch Road, Stanford, CA 94305, USA
Neurol Res 30:952-9. 2008..The purpose of this study was to characterize changes in tumor vascular permeability, vascular density and vessel morphology in vivo during angiogenesis... - microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4)Zhanhong Wu
The Molecular Imaging Program at Stanford MIPS, Department of Radiology and Bio X Program, Stanford University School of Medicine, 1201 Welch Road, Stanford, CA 94305, USA
J Nucl Med 48:1536-44. 2007..Here we report an example of (18)F-labeled tetrameric RGD peptide for PET of alpha(v)beta(3) expression in both xenograft and spontaneous tumor models... - Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing miceWeibo Cai
Department of Radiology and Bio X Program, The Molecular Imaging Program at Stanford, Stanford University School of Medicine, 1201 Welch Road, Stanford, CA 94305 5484, USA
Eur J Nucl Med Mol Imaging 34:2024-36. 2007..Although many recent reports have focused on blocking the EphA2 signaling pathway in cancer, the in vivo imaging of EphA2 has not yet been investigated... - Integrin-targeted imaging and therapy with RGD4C-TNF fusion proteinHui Wang
Molecular Imaging Program at Stanford, Department of Radiology and Bio X Program, Stanford University School of Medicine, 1201 Welch Road, P095, Stanford, CA 94305 5484, USA
Mol Cancer Ther 7:1044-53. 2008..Ex vivo tissue staining confirmed specific cytotoxicity of RGD4C-TNF against integrin-positive tumor cells and tumor vasculature... - PET of vascular endothelial growth factor receptor expressionWeibo Cai
Molecular Imaging Program at Stanford (MIPS, Department of Radiology and Bio-X Program, Stanford University School of Medicine, Stanford, CA 94305-5484, USA
J Nucl Med 47:2048-56. 2006.... - Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dotsKai Chen
Department of Radiology and Bio X Program, School of Medicine, Stanford University, Stanford, CA 94305 5484, USA
Eur J Nucl Med Mol Imaging 35:2235-44. 2008..The development of a dual-function positron emission tomography (PET)/near-infrared fluorescence (NIRF) probe might allow the accurate assessment of the tumor-targeting efficacy of QDs... - Quantitative PET imaging of VEGF receptor expressionKai Chen
Department of Radiology and Bio X Program, Stanford University School of Medicine, CA 94305 5484, USA
Mol Imaging Biol 11:15-22. 2009..Quantitative positron emission tomography (PET) imaging of VEGFR will facilitate the planning of whether, and when, to start anti-angiogenic treatment and enable more robust and effective monitoring of such treatment... - A new PET tracer specific for vascular endothelial growth factor receptor 2Hui Wang
The Molecular Imaging Program at Stanford, Department of Radiology and Bio X Program, Stanford University School of Medicine, 1201 Welch Road, Stanford, CA 94305 5484, USA
Eur J Nucl Med Mol Imaging 34:2001-10. 2007..The aim of this study was to develop a VEGFR-2-specific PET tracer... - In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3Weibo Cai
The Molecular Imaging Program at Stanford, Department of Radiology and Bio-X Program, Stanford University School of Medicine, Stanford, CA 94305-5484, USA
Cancer Res 66:9673-81. 2006..Chemotherapeutics or radiotherapeutics using Abegrin as the delivering vehicle may also be effective in treating integrin alpha(v)beta(3)-positive tumors... - Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiformeAnand Veeravagu
Molecular Imaging Program at Stanford, Department of Radiology and Bio X Program, Stanford University School of Medicine, Stanford, California 94305 5484, USA
Clin Cancer Res 14:7330-9. 2008..The purpose of this study was to evaluate the efficacy of a novel 90Y-Abegrin radioimmunotherapeutic agent in murine xenograft glioblastoma models with noninvasive in vivo molecular imaging modalities... - PET imaging of acute and chronic inflammation in living miceQizhen Cao
The Molecular Imaging Program at Stanford, Department of Radiology and Bio X Program, Stanford University School of Medicine, Stanford, CA 94305 5484, USA
Eur J Nucl Med Mol Imaging 34:1832-42. 2007..In this study, we evaluated the 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced acute and chronic inflammation in living mice by PET imaging of TNF-alpha and integrin alpha(v)beta(3) expression... - 18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expressionZhanhong Wu
The Molecular Imaging Program at Stanford, Department of Radiology and Bio X Program, Stanford University School of Medicine, Stanford, CA 94305 5484, USA
Eur J Nucl Med Mol Imaging 34:1823-31. 2007..The goal of this study was to improve the radiolabeling yield, without compromising the tumor targeting efficiency and in vivo kinetics, by incorporating a hydrophilic bifunctional mini-PEG spacer... - Non-invasive PET imaging of EGFR degradation induced by a heat shock protein 90 inhibitorGang Niu
The Molecular Imaging Program at Stanford, Department of Radiology and Bio X Program, Stanford University School of Medicine, 1201 Welch Rd, P095, Stanford, CA 94305 5484, USA
Mol Imaging Biol 10:99-106. 2008..The aim of this study is to non-invasively monitor the epidermal growth factor receptor (EGFR) response to a Hsp90 inhibitor-17-AAG treatment in a PC-3 prostate cancer model... - PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabodyWeibo Cai
Molecular Imaging Program at Stanford, Department of Radiology, Stanford University School of Medicine, Stanford, California 94305 5484, USA
J Nucl Med 48:304-10. 2007..66 diabody, a genetically engineered noncovalent dimer of single-chain variable fragments, for small-animal PET imaging of CEA expression in xenograft-bearing mice... - Radiolabeled γ-AApeptides: a new class of tracers for positron emission tomographyYunan Yang
Department of Radiology, University of Wisconsin Madison, WI 53705, USA
Chem Commun (Camb) 48:7850-2. 2012.... - In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographeneHao Hong
Department of Radiology, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
ACS Nano 6:2361-70. 2012..Since poor extravasation is a major hurdle for nanomaterial-based tumor targeting in vivo, this study also establishes CD105 as a promising vascular target for future cancer nanomedicine... - Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibodyWeibo Cai
The Molecular Imaging Program at Stanford MIPS, Department of Radiology and Bio X Program, Stanford University School of Medicine, 1201 Welch Rd P095, Stanford, CA 94305 5484, USA
Eur J Nucl Med Mol Imaging 34:850-8. 2007..Here we report for the first time the quantitative positron emission tomography (PET) imaging of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab... - Multimodality imaging of IL-18--binding protein-Fc therapy of experimental lung metastasisQizhen Cao
The Molecular Imaging Program at Stanford, Department of Radiology and Bio X Program, Stanford University School of Medicine, 1201 Welch Road, Stanford, CA 94305, USA
Clin Cancer Res 14:6137-45. 2008.... - Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapyAnand Veeravagu
Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305 5484, USA
Recent Pat Anticancer Drug Discov 2:59-71. 2007..This review will focus on patents which target VEGF-[A-F] and/or VEGFR-[1-3] for use in anti-cancer treatment... - Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105Hao Hong
Department of Radiology, University of Wisconsin Madison, Madison, WI 53705, USA
Eur J Nucl Med Mol Imaging 39:138-48. 2012..The goal of this study was to develop an (89)Zr-based PET tracer for noninvasive imaging of CD105 expression... - Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTAYin Zhang
Department of Medical Physics, University of Wisconsin Madison, Madison, Wisconsin, United States of America
PLoS ONE 6:e28005. 2011..In conclusion, this study confirmed that NOTA is a superior chelator to DOTA for PET imaging with (64)Cu-labeled TRC105... - Combination of integrin siRNA and irradiation for breast cancer therapyQizhen Cao
Molecular Imaging Program at Stanford and Bio-X, Department of Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA
Biochem Biophys Res Commun 351:726-32. 2006..This study, with further optimization, may provide a simple and highly efficient treatment strategy for breast cancer as well as other integrin alpha(v)beta(3)-positive cancer types... - Positron emission tomography imaging of poststroke angiogenesisWeibo Cai
The Molecular Imaging Program at Stanford, Department of Radiology, Stanford University, Stanford, CA, USA
Stroke 40:270-7. 2009..In this study, we imaged VEGFR expression with positron emission tomography (PET) to noninvasively analyze poststroke angiogenesis... - A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expressionWeibo Cai
Molecular Imaging Program at Stanford (MIPS) and Bio-X Program, Department of Radiology, Stanford University School of Medicine, Stanford, California 94305-5484, USA
J Nucl Med 47:1172-80. 2006..The new synthon 18F-FBEM developed in this study will also be useful for radiolabeling of other thiolated biomolecules... - Immuno-PET of tissue factor in pancreatic cancerHao Hong
Department of Radiology, University of Wisconsin, Madison, WI, USA
J Nucl Med 53:1748-54. 2012..Upregulation of tissue factor (TF) expression leads to increased patient morbidity and mortality in many solid tumor types. The goal of this study was to develop a PET tracer for imaging of TF expression in pancreatic cancer... - Monitoring of the biological response to murine hindlimb ischemia with 64Cu-labeled vascular endothelial growth factor-121 positron emission tomographyJurgen K Willmann
Department of Radiology and Bio X Program, Stanford University School of Medicine, Stanford, Calif, USA
Circulation 117:915-22. 2008.... - In vivo bioluminescence tumor imaging of RGD peptide-modified adenoviral vector encoding firefly luciferase reporter geneGang Niu
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA
Mol Imaging Biol 9:126-34. 2007..The goal of this study is to demonstrate the feasibility of chemically modified human adenovirus (Ad) vectors for tumor retargeting... - Gold Nanorods Conjugated with Doxorubicin and cRGD for Combined Anticancer Drug Delivery and PET ImagingYuling Xiao
1 Department of Biomedical Engineering and Wisconsin Institutes for Discovery, University of Wisconsin Madison, Madison, WI 53706, USA
Theranostics 2:757-68. 2012.... - Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGelAndrew R Hsu
The Molecular Imaging Program at Stanford, Department of Radiology and Bio X Program, Stanford University School of Medicine, Stanford, California 94305 5484, USA
J Nucl Med 48:445-54. 2007.... - Cancer-targeted optical imaging with fluorescent zinc oxide nanowiresHao Hong
Department of Radiology and Medical Physics, University of Wisconsin Madison, Madison, Wisconsin 53705, United States
Nano Lett 11:3744-50. 2011.... - Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imagingWeibo Cai
Molecular Imaging Program at Stanford MIPS, Department of Radiology and Bio X Program, Stanford University School of Medicine, Stanford, California 94305, USA
Nat Protoc 3:89-96. 2008..In general, QD conjugation and in vitro validation of the peptide-conjugated QDs can be accomplished within 1-2 d; in vivo imaging will take another 1-2 d depending on the experimental design... - Integrin alpha v beta 3 antagonists for anti-angiogenic cancer treatmentAndrew R Hsu
Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA
Recent Pat Anticancer Drug Discov 2:143-58. 2007..This review will focus on the key points and distinguishing factors for patents which use antibodies, RGD peptides, non-RGD peptides, peptidomimetics, and amine salts as alpha(v)beta(3) antagonists... - PET imaging of CD105/endoglin expression with a (61/64)Cu-labeled Fab antibody fragmentYin Zhang
Department of Medical Physics, University of Wisconsin Madison, 1111 Highland Avenue, Madison, WI, 53705 2275, USA
Eur J Nucl Med Mol Imaging 40:759-67. 2013..e., endoglin), and investigate its potential for PET imaging of tumor angiogenesis in a small-animal model after (61/64)Cu labeling... - Tumor vasculature targeting and imaging in living mice with reduced graphene oxideSixiang Shi
Materials Science Program, University of Wisconsin Madison, WI, USA
Biomaterials 34:3002-9. 2013..Since RGO exhibits desirable properties for photothermal therapy, the tumor-specific RGO conjugate developed in this work may serve as a promising theranostic agent that integrates imaging and therapeutic components... - Graphene: a versatile nanoplatform for biomedical applicationsYin Zhang
Department of Medical Physics, University of Wisconsin Madison, WI, USA
Nanoscale 4:3833-42. 2012..The future of graphene-based nanomaterials in biomedicine looks brighter than ever, and it is expected that they will find a wide range of biomedical applications with future research effort and interdisciplinary collaboration... - In vivo imaging of RNA interferenceHao Hong
Departments of Radiology and Medical Physics and University of Wisconsin Carbone Cancer Center, University of Wisconsin Madison, Madison, Wisconsin 53705, USA
J Nucl Med 51:169-72. 2010..Incorporation of suitable molecular imaging techniques into future RNAi-based clinical trials will provide more pieces of the puzzle, thus facilitating the transformation of RNAi into a powerful therapeutic modality in the clinic... - In vivo targeting and positron emission tomography imaging of tumor vasculature with (66)Ga-labeled nano-grapheneHao Hong
Department of Radiology, University of Wisconsin Madison, Madison, WI 53705 2275, USA
Biomaterials 33:4147-56. 2012..Successful demonstration of in vivo tumor targeting with GO, along with the versatile chemistry of graphene-based nanomaterials, makes them suitable nanoplatforms for future biomedical research such as cancer theranostics... - Positron emission tomography imaging of tumor angiogenesis with a 66Ga-labeled monoclonal antibodyJonathan W Engle
Department of Medical Physics, University of Wisconsin Madison, Wisconsin, United States
Mol Pharm 9:1441-8. 2012..Successful PET imaging with high specific activity (66)Ga (>700 GBq/μmol has been achieved) as the radiolabel opens many new possibilities for future PET research with antibodies or other targeting ligands... - Semiconductor quantum dots for in vivo imagingZi Bo Li
The Molecular Imaging Program at Stanford MIPS, Department of Radiology and Bio X Program, Stanford University, Stanford, CA 94305, USA
J Nanosci Nanotechnol 7:2567-81. 2007..The integration of quantum dots with other imaging techniques is also expected to give rise to a new generation of multifunctional probes for biomedical applications... - How molecular imaging is speeding up antiangiogenic drug developmentWeibo Cai
The Molecular Imaging Program at Stanford, Department of Radiology and Bio-X Program, Stanford University School of Medicine, 1201 Welch Road, P095, Stanford, CA 94305-5484, USA
Mol Cancer Ther 5:2624-33. 2006..Molecular imaging has enormous potential in improving the efficiency of the drug development process, including the specific area of antiangiogenic drugs... - Chapter 7. Molecular imaging of tumor vasculatureWeibo Cai
Stanford University School of Medicine, Stanford, California, USA
Methods Enzymol 445:141-76. 2008.... - Positron Emission Tomography Imaging of Tumor Angiogenesis with a (61/64)Cu-Labeled F(ab')(2) Antibody FragmentHao Hong
Department of Radiology and Department of Medical Physics, University of Wisconsin Madison, Madison, Wisconsin, United States
Mol Pharm 10:709-16. 2013.... - Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imagingYuling Xiao
Department of Biomedical Engineering and Wisconsin Institutes for Discovery, University of Wisconsin Madison, Madison, WI 53706, USA
Biomaterials 33:3071-82. 2012.... - Positron emission tomography and optical imaging of tumor CD105 expression with a dual-labeled monoclonal antibodyYin Zhang
Department of Medical Physics, University of Wisconsin Madison, Madison, Wisconsin, United States
Mol Pharm 9:645-53. 2012..Successful PET/NIRF imaging of CD105 expression warrants further investigation and clinical translation of dual-labeled TRC105-based imaging agents... - In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesisYunan Yang
Department of Radiology, University of Wisconsin Madison, Madison, WI, USA
Eur J Nucl Med Mol Imaging 38:2066-76. 2011..The goal of this study is to evaluate tumor angiogenesis in a mouse model by near-infrared fluorescence (NIRF) imaging of CD105 expression... - Multimodality imaging of the HER-kinase axis in cancerWeibo Cai
The Molecular Imaging Program at Stanford MIPS, Department of Radiology and Bio X Program, Stanford University School of Medicine, 1201 Welch Rd, P095, Stanford, CA 94305 5484, USA
Eur J Nucl Med Mol Imaging 35:186-208. 2008..Successful development of new HER-kinase-targeted imaging agents with optimal in vivo stability, targeting efficacy, and desirable pharmacokinetics for clinical translation will enable maximum benefit in cancer patient management... - Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonismWeibo Cai
Molecular Imaging Program at Stanford, Department of Radiology and Bio-X Program, Stanford University School of Medicine, Stanford, CA 94305-5484, USA
Anticancer Agents Med Chem 6:407-28. 2006..Lastly, integrin targeted delivery (drugs, genes, and radioisotopes) and imaging (optical, MRI, ultrasound, SPECT, and PET) is discussed in detail... - Positron emission tomography imaging of CD105 expression during tumor angiogenesisHao Hong
Department of Radiology, University of Wisconsin Madison, Madison, WI 53705 2275, USA
Eur J Nucl Med Mol Imaging 38:1335-43. 2011..The goal of this study was to develop a positron emission tomography (PET) tracer for imaging CD105 expression... - PET tracers based on Zirconium-89Yin Zhang
Departments of Radiology and Medical Physics, School of Medicine and Public Health, University ofWisconsin Madison, Madison, WI 53705 2275, USA
Curr Radiopharm 4:131-9. 2011.... - Imaging with Raman spectroscopyYin Zhang
Department Medical Physics, School of Medicine and Public Health, University of Wisconsin Madison, Madison, WI 53705 2275, USA
Curr Pharm Biotechnol 11:654-61. 2010..It is expected that imaging with Raman Spectroscopy will continue to be a dynamic research field over the next decade... - Molecular imaging of human epidermal growth factor receptor 2 (HER-2) expressionGang Niu
The Molecular Imaging Program at Stanford, Department of Radiology, Stanford University School of Medicine, Stanford, California 94305, USA
Front Biosci 13:790-805. 2008..Successful development of new HER-2 targeted imaging agents with optimal in vivo stability, targeting efficacy, and desirable pharmacokinetics for clinical translation will enable maximum benefit in cancer patient management... - Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjectsWeibo Cai
Molecular Imaging Program (MIPS, Department of Radiology, Stanford University School of Medicine, Stanford, California 94305, USA
Nano Lett 6:669-76. 2006..The results reported here open up new perspectives for integrin-targeted near-infrared optical imaging and may aid in cancer detection and management including imaging-guided surgery... - Positron emission tomography imaging of prostate cancerHao Hong
Department of Radiology, School of Medicine and Public Health, University of Wisconsin Madison, 1111 Highland Avenue, Madison, WI 53705 2275, USA
Amino Acids 39:11-27. 2010..Lastly, we will identify future directions for the development of novel PET tracers for PCa imaging, which may eventually lead to personalized management of PCa patients... - Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimersYun Wu
Molecular Imaging Program at Stanford (MIPS, Department of Radiology and Bio-X Program, Stanford University School of Medicine, 1201 Welch Rd, P095, Stanford, CA 94305-5484, USA
Mol Imaging Biol 8:226-36. 2006..CONCLUSIONS: Noninvasive NIR fluorescence imaging is able to detect and semiquantify tumor integrin expression based upon the highly potent tetrameric RGD peptide probe... - Non-invasive imaging of human embryonic stem cellsHao Hong
Department of Radiology, School of Medicine and Public Health, University of Wisconsin Madison, Madison, WI 53705 2275, USA
Curr Pharm Biotechnol 11:685-92. 2010..Continued evolvement of non-invasive imaging techniques will undoubtedly contribute to significant advances in understanding stem cell biology and mechanisms of action... - Multimodality imaging of nitric oxide and nitric oxide synthasesHao Hong
Department of Radiology, School of Medicine and Public Health, University of Wisconsin Madison, Madison, Wisconsin 53705 2275, USA
Free Radic Biol Med 47:684-98. 2009..Successful development of novel NO/NOS imaging agents with optimal in vivo stability and desirable pharmacokinetics for clinical translation will enable the maximum benefit in patient management... - Nanoplatforms for targeted molecular imaging in living subjectsWeibo Cai
Molecular Imaging Program at Stanford MIPS, Department of Radiology and Bio X Program, Stanford University, Stanford, CA 94305, USA
Small 3:1840-54. 2007..In this Review, we will summarize the current state-of-the-art of nanoplatforms for targeted molecular imaging in living subjects... - Non-invasive cell tracking in cancer and cancer therapyHao Hong
Department of Radiology, School of Medicine and Public Health, University of Wisconsin Madison, 1111 Highland Avenue, Room 7137, Madison, WI 53705, USA
Curr Top Med Chem 10:1237-48. 2010..MRI, radionuclide-based imaging techniques, and reporter gene-based approaches will each have their own niches towards the same ultimate goal: personalized medicine for cancer patients... - Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expressionWeibo Cai
The Molecular Imaging Program at Stanford MIPS, Department of Radiology and Bio X Program, Stanford University School of Medicine, Stanford, California 94305, USA
Front Biosci 12:4267-79. 2007..With the development of new tracers with better targeting efficacy and desirable pharmacokinetics, clinical translation will be critical for the maximum benefit of VEGF/VEGFR targeted imaging agents... - Imaging of Abdominal Aortic Aneurysm: the present and the futureHao Hong
Department of Radiology, School of Medicine and Public Health, University of Wisconsin Madison, Madison, WI 53705 2275, USA
Curr Vasc Pharmacol 8:808-19. 2010..Equally important, the right imaging probe will also allow scientists/clinicians to acquire critical data during AAA development and to more accurately evaluate the efficacy of potential treatments... - Molecular imaging with SERS-active nanoparticlesYin Zhang
Department of Medical Physics, University of Wisconsin Madison, Room 7137, 1111 Highland Ave, Madison, WI 53705 2275, USA
Small 7:3261-9. 2011..It is expected that SERS-based imaging will continue to be a dynamic research field over the next decade... - Multimodality Imaging of Integrin α(v)β(3) ExpressionYin Zhang
1 Departments of Radiology and Medical Physics, School of Medicine and Public Health, University of Wisconsin Madison, USA
Theranostics 1:135-48. 2011..The next decade will likely witness further growth and continued prosperity of molecular imaging studies focusing on integrin α(v)β(3), which can eventually impact patient management... - 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancerXianzhong Zhang
Molecular Imaging Program at Stanford (MIPS, Department of Radiology and Bio-X Program, Stanford University School of Medicine, Stanford, California 94305-5484, USA
J Nucl Med 47:492-501. 2006..CONCLUSION: This study demonstrates that 18F-FB-[Lys3]BBN and PET are suitable for detecting GRPR-positive prostate cancer in vivo... - Anatomical and molecular imaging of skin cancerHao Hong
Departments of Radiology and Medical Physics, School of Medicine and Public Health, University of Wisconsin Madison, Madison, Wisconsin, USA
Clin Cosmet Investig Dermatol 1:1-17. 2008..It is likely that this situation will change in the near future and molecular imaging will truly play an important role in personalized medicine of melanoma patients... - Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2Xianzhong Zhang
Molecular Imaging Program at Stanford, MIPS, and Bio X Program, Department of Radiology, Stanford University, California 94305 5484, USA
J Nucl Med 47:113-21. 2006..We labeled the dimeric RGD peptide E[c(RGDyK)](2) with (18)F and evaluated its tumor-targeting efficacy and pharmacokinetics of (18)F-FB-E[c(RGDyK)](2) ((18)F-FRGD2)... - Imaging of VEGF receptor in a rat myocardial infarction model using PETMartin Rodriguez-Porcel
Molecular Imaging Program at Stanford, Department of Radiology, Division of Nuclear Medicine, Stanford University, Stanford, CA 94305 5427, USA
J Nucl Med 49:667-73. 2008..We have developed a PET tracer (64Cu-DOTA-VEGF121 [DOTA is 1,4,7,10-tetraazadodecane-N,N',N'',N'''-tetraacetic acid]) to image VEGF receptor (VEGFR) expression after MI in the living subject...